Evgen Pharma PLC (EVG)

London
6.12
-0.09(-1.37%)
  • Volume:
    159,776
  • Bid/Ask:
    6.10/6.30
  • Day's Range:
    6.12 - 6.12

EVG Overview

Prev. Close
6.2
Day's Range
6.12-6.12
Revenue
190K
Open
6.35
52 wk Range
4.22-15.27
EPS
-0.02
Volume
159,776
Market Cap
17.04M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,299,080
P/E Ratio
-
Beta
1.57
1-Year Change
-47.02%
Shares Outstanding
274,888,117
Next Earnings Date
08 Dec 2021
What is your sentiment on Evgen Pharma PLC?
or
Vote to see community's results!

Evgen Pharma PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsSellSellBuySellStrong Sell
SummaryStrong SellStrong SellNeutralSellStrong Sell

Evgen Pharma PLC Company Profile

Evgen Pharma PLC Company Profile

Employees
8

Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Read More
  • just won 2 million bullish
    1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.